IP Library › Granted Patent US 9,745,364
Granted Patent B2
US 9,745,364 · App. 13/354,774 · Granted Aug 29, 2017

Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,745,364
App. No.
13/354,774
Granted
Aug 29, 2017
Kind
B2
Abstract

This invention provides an anti-idiotype antibody that binds to the antigen-binding region of an antibody encoded by antibody genes selected from the group consisting of Set I, Set II, Set III, Set IV, Set V, Set VIa, Set VIb, Set VIc, Set VId, Set VIe, Set VII, and Set VIII, hybridomas and methods of treatments using such.

Claims (11)

1. An isolated human or humanized anti-idiotype antibody that specifically binds to the antigen-binding region of an antibody selected from the group consisting of (i) an antibody with an H chain comprising SEQ ID NO:167 and an L chain comprising SEQ ID NO:221, (ii) an antibody with an H chain comprising SEQ ID NO:181 and an L chain comprising SEQ ID NO:229, (iii) an antibody with an H chain comprising SEQ ID NO:197 and an L chain comprising SEQ ID NO:239, (iv) an antibody with an H chain comprising SEQ ID NO:208 and an L chain comprising SEQ ID NO:239, (v) an antibody with an H chain comprising SEQ ID NO:207 and an L chain comprising SEQ ID NO:239, (vi) an antibody with an H chain comprising SEQ ID NO:211 and an L chain comprising SEQ ID NO:239 (vii) an antibody with an H chain comprising SEQ ID NO:220 and an L chain comprising SEQ ID NO:239, and (viii) an antibody with an H chain comprising SEQ ID NO:172 and an L chain comprising SEQ ID NO:225.

2. The anti-idiotype antibody of claim 1 , which is a human antibody.

3. The anti-idiotype antibody of claim 1 , which is a humanized antibody.

4. A mixture of two or more of the anti-idiotype antibodies of claim 1 .

5. A pharmaceutical composition comprising at least one of the anti-idiotype antibodies of claim 1 , in a pharmaceutically acceptable excipient.

6. The anti-idiotype antibody of claim 1 , further comprising a cellular toxin.

7. The anti-idiotype antibody of claim 6 , wherein the cellular toxin is a chemotherapeutic agent.

8. The anti-idiotype antibody of claim 1 , further comprising a detectable moiety.

9. A hybridoma producing the antibody of claim 1 .

10. A method of treating a patient having B-CLL B cells comprising antibody genes from VH1-69/D3-16/JH3/VLκA27/JLκ1/κ4 (Set IV), VH1-69/D3-10/JH6/VLλ1c/JLλ1 (Set V), VH1-02/D6-19/JH4/VLκO12/2/JLκ1/κ2 (Set VIa), VH1-03/D6-19/JH4/VLκO12/2/JLκ1/κ2 (Set VIb), VH1-18/D6-19/JH4/VLκO12/2/JLκ1 (Set VIc), VH1-46/D6-19/JH4 (Set VId), VH5-51/D6-19/JH4/VLκO12/2/JLκ2 (Set VIe), or VH1-69/D2-2/JH6/VLκL6/2/JLκ3 (Set VIII), the method comprising administering to the patient the anti-idiotype antibody of claim 1 in an amount effective to treat B-CLL.

11. The method of claim 10 , wherein the anti-idiotype antibody further comprises a cellular toxin.

Assignments (2)
CHANGE OF NAME Recorded Aug 20, 2019
From: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
To: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Reel/Frame 050102/0485 →
CONFIRMATORY LICENSE Recorded Sep 8, 2014
From: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033695/0294 →